{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T09:05:12Z","timestamp":1740128712062,"version":"3.37.3"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T00:00:00Z","timestamp":1667347200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,5,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Humoral immune responses may be critical for preventing, controlling, and\/or eliminating human papillomavirus (HPV) infection. We analyzed humoral response to natural HPV infection considering phylogenetic relatedness among unvaccinated women.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We included 399 young women attending university\/college in Montreal, Canada who were participants of the HITCH cohort. Participants provided blood samples at baseline and 5 follow-up visits. Antibody response to bacterially expressed L1 and E6 glutathione S-transferase (GST) fusion proteins, and virus-like particles (VLP-L1) of Alphapapillomavirus types were measured using multiplex serology. We assessed correlations and associations between HPV types at baseline using Pearson correlation coefficients (r) and univariable linear regressions.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>At baseline, &amp;gt; 40% were seropositive for GST-L1 antibodies of at least 1 HPV type. Strong correlations between GST-L1 were observed for \u03b19 HPV types: 58\u201352 (r = 0.86), 58\u201333 (r = 0.75), 33\u201352 (r = 0.72), and between GST-E6: 52\u201311 (r = 0.84), 52\u201318 (r = 0.79), 58\u201333 (r = 0.78), 35\u201311 (r = 0.76). HPV16 VLP-L1 moderately explained variability in HPV16 GST-L1 (regression coefficient [b] = 0.38, R2 = 43.1%), and HPV45 GST-L1 in HPV18 GST-L1 (b = 0.68, R2 = 42.8%). GST-E6 antibodies accounted for a low to moderate proportion of variability in HPV16 and HPV18 GST-E6 (R2 = 6.4%\u201362.2%).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Associations between naturally induced HPV-specific antibodies depend on phylogenetic relatedness.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/infdis\/jiac437","type":"journal-article","created":{"date-parts":[[2022,11,2]],"date-time":"2022-11-02T17:33:20Z","timestamp":1667410400000},"page":"1173-1184","source":"Crossref","is-referenced-by-count":2,"title":["Serologic Response to Human Papillomavirus Genotypes Among Unvaccinated Women: Findings From the HITCH Cohort Study"],"prefix":"10.1093","volume":"227","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5808-0179","authenticated-orcid":false,"given":"Samantha","family":"Morais","sequence":"first","affiliation":[{"name":"Division of Cancer Epidemiology, McGill University , Montreal, Quebec , Canada"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6254-2233","authenticated-orcid":false,"given":"Michel D","family":"Wissing","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology, McGill University , Montreal, Quebec , Canada"}]},{"given":"Farzin","family":"Khosrow-Khavar","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology, McGill University , Montreal, Quebec , Canada"}]},{"given":"Ann N","family":"Burchell","sequence":"additional","affiliation":[{"name":"Department of Family and Community Medicine and MAP Centre for Urban Health Solutions, Li Ka Shing Knowledge Institute, St Michael's Hospital, Unity Health Toronto , Toronto, Ontario , Canada"}]},{"given":"Pierre-Paul","family":"Tellier","sequence":"additional","affiliation":[{"name":"Department of Family Medicine, McGill University , Montreal, Quebec , Canada"}]},{"given":"Fran\u00e7ois","family":"Coutl\u00e9e","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology, McGill University , Montreal, Quebec , Canada"},{"name":"Laboratoire de Virologie Mol\u00e9culaire, Centre de Recherche du Centre Hospitalier de l'Universit\u00e9 de Montr\u00e9al, et D\u00e9partement de Microbiologie, Infectiologie et Immunologie, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al, Qu\u00e9bec , Canada"}]},{"given":"Tim","family":"Waterboer","sequence":"additional","affiliation":[{"name":"Infections and Cancer Epidemiology Division, German Cancer Research Center , Heidelberg , Germany"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5190-0370","authenticated-orcid":false,"given":"Mariam","family":"El-Zein","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology, McGill University , Montreal, Quebec , Canada"}]},{"given":"Eduardo L","family":"Franco","sequence":"additional","affiliation":[{"name":"Division of Cancer Epidemiology, McGill University , Montreal, Quebec , Canada"}]}],"member":"286","published-online":{"date-parts":[[2022,11,2]]},"reference":[{"key":"2023051202560699300_jiac437-B1","doi-asserted-by":"crossref","first-page":"S6","DOI":"10.1016\/j.ygyno.2007.07.076","article-title":"The spectrum and clinical sequelae of human papillomavirus infection","volume":"107","author":"Monk","year":"2007","journal-title":"Gynecol Oncol"},{"key":"2023051202560699300_jiac437-B2","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/OLQ.0000000000000193","article-title":"The estimated lifetime probability of acquiring human papillomavirus in the United States","volume":"41","author":"Chesson","year":"2014","journal-title":"Sex Transm Dis"},{"key":"2023051202560699300_jiac437-B3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00007435-199017010-00004","article-title":"Prevalence, incidence, and estimated life-time risk of cervical human papillomavirus infections in a nonselected Finnish female population","volume":"17","author":"Syrj\u00e4nen","year":"1990","journal-title":"Sex Transm Dis"},{"key":"2023051202560699300_jiac437-B4","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1086\/315086","article-title":"Epidemiology of acquisition and clearance of cervical human papillomavirus infection in women from a high-risk area for cervical cancer","volume":"180","author":"Franco","year":"1999","journal-title":"J Infect Dis"},{"key":"2023051202560699300_jiac437-B5","first-page":"421","article-title":"Incidence, clearance and predictors of human papillomavirus infection in women","volume":"168","author":"Sellors","year":"2003","journal-title":"CMAJ"},{"key":"2023051202560699300_jiac437-B6","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1086\/596050","article-title":"Factors associated with acquisition and clearance of human papillomavirus infection in a cohort of US men: a prospective study","volume":"199","author":"Lu","year":"2009","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"2023051202560699300_jiac437-B7","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ypmed.2011.08.017","article-title":"Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies","volume":"53","author":"Tota","year":"2011","journal-title":"Prev Med"},{"issue":"Suppl 10","key":"2023051202560699300_jiac437-B8","doi-asserted-by":"crossref","first-page":"K17","DOI":"10.1016\/j.vaccine.2008.06.021","article-title":"Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions","volume":"26","author":"Giuliano","year":"2008","journal-title":"Vaccine"},{"key":"2023051202560699300_jiac437-B9","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/ijc.30059","article-title":"The causal role of human papillomavirus infections in non-anogenital cancers. It's time to ask for the functional evidence","volume":"139","author":"von Knebel Doeberitz","year":"2016","journal-title":"Int J Cancer"},{"key":"2023051202560699300_jiac437-B10","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14787210.2020.1750950","article-title":"Natural and vaccine-induced B cell-derived systemic and mucosal humoral immunity to human papillomavirus","volume":"18","author":"Mboumba Bouassa","year":"2020","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2023051202560699300_jiac437-B11","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.virol.2004.03.033","article-title":"Classification of papillomaviruses","volume":"324","author":"de Villiers","year":"2004","journal-title":"Virology"},{"key":"2023051202560699300_jiac437-B12","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1158\/0008-5472.CAN-05-3066","article-title":"Age-related changes of the cervix influence human papillomavirus type distribution","volume":"66","author":"Castle","year":"2006","journal-title":"Cancer Res"},{"key":"2023051202560699300_jiac437-B13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1750-9378-4-8","article-title":"Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline","volume":"4","author":"Schiffman","year":"2009","journal-title":"Infect Agent Cancer"},{"key":"2023051202560699300_jiac437-B14","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.virol.2005.04.002","article-title":"The carcinogenicity of human papillomavirus types reflects viral evolution","volume":"337","author":"Schiffman","year":"2005","journal-title":"Virology"},{"key":"2023051202560699300_jiac437-B15","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/jnci\/djq562","article-title":"Human papillomavirus testing in the prevention of cervical cancer","volume":"103","author":"Schiffman","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2023051202560699300_jiac437-B16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S1470-2045(09)70096-8","article-title":"A review of human carcinogens\u2014part B: biological agents","volume":"10","author":"Bouvard","year":"2009","journal-title":"Lancet Oncol"},{"key":"2023051202560699300_jiac437-B17","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa021641","article-title":"Epidemiologic classification of human papillomavirus types associated with cervical cancer","volume":"348","author":"Mu\u00f1oz","year":"2003","journal-title":"N Engl J Med"},{"key":"2023051202560699300_jiac437-B18","volume":"90","author":"International Agency for Research on Cancer","year":"2007","journal-title":"IARC Monographs on the evaluation of carcinogenic risks to humans. Human papillomaviruses, vol"},{"key":"2023051202560699300_jiac437-B19","doi-asserted-by":"crossref","first-page":"e74797","DOI":"10.1371\/journal.pone.0074797","article-title":"Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses","volume":"8","author":"Scherpenisse","year":"2013","journal-title":"PLoS One"},{"key":"2023051202560699300_jiac437-B20","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1006\/scbi.1999.0146","article-title":"The serological response to papillomaviruses","volume":"9","author":"Dillner","year":"1999","journal-title":"Semin Cancer Biol"},{"key":"2023051202560699300_jiac437-B21","doi-asserted-by":"crossref","first-page":"379","DOI":"10.3109\/00365540903501608","article-title":"Natural seroconversion to high-risk human papillomaviruses (hrHPVs) is not protective against related HPV genotypes","volume":"42","author":"Palmroth","year":"2010","journal-title":"Scand J Infect Dis"},{"issue":"Suppl 3","key":"2023051202560699300_jiac437-B22","first-page":"S361","article-title":"Serology for human papillomavirus","volume":"45","author":"Coursaget","year":"2003","journal-title":"Salud Publica Mex"},{"key":"2023051202560699300_jiac437-B23","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1038\/sj.bjc.6601272","article-title":"Seroprevalence of human papillomavirus-16, -18, -31, and -45 in a population-based cohort of 10000 women in Costa Rica","volume":"89","author":"Wang","year":"2003","journal-title":"Br J Cancer"},{"key":"2023051202560699300_jiac437-B24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000091","article-title":"Seroprevalence of 34 human papillomavirus types in the German general population","volume":"4","author":"Michael","year":"2008","journal-title":"PLoS Pathog"},{"key":"2023051202560699300_jiac437-B25","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1093\/infdis\/jiv753","article-title":"Natural acquired immunity against subsequent genital human papillomavirus infection: a systematic review and meta-analysis","volume":"213","author":"Beachler","year":"2016","journal-title":"J Infect Dis"},{"key":"2023051202560699300_jiac437-B26","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1086\/517428","article-title":"Stability over time of serum antibody levels to human papillomavirus type 16","volume":"177","author":"af Geijersstam","year":"1998","journal-title":"J Infect Dis"},{"key":"2023051202560699300_jiac437-B27","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1086\/315498","article-title":"Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection","volume":"181","author":"Carter","year":"2000","journal-title":"J Infect Dis"},{"key":"2023051202560699300_jiac437-B28","doi-asserted-by":"crossref","first-page":"2612","DOI":"10.1002\/ijc.22131","article-title":"Seroprevalence atlas of infections with oncogenic and non-oncogenic human papillomaviruses in Finland in the 1980s and 1990s","volume":"119","author":"Lehtinen","year":"2006","journal-title":"Int J Cancer"},{"key":"2023051202560699300_jiac437-B29","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1016\/j.vaccine.2006.04.068","article-title":"Immunologic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and 18","volume":"24","author":"Villa","year":"2006","journal-title":"Vaccine"},{"key":"2023051202560699300_jiac437-B30","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.virol.2010.07.046","article-title":"Prevalence and stability of antibodies to 37 human papillomavirus types\u2013a population-based longitudinal study","volume":"407","author":"Antonsson","year":"2010","journal-title":"Virology"},{"key":"2023051202560699300_jiac437-B31","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1055-9965.EPI-03-0191","article-title":"Natural history of human papillomavirus type 16 virus-like particle antibodies in young women","volume":"13","author":"Ho","year":"2004","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2023051202560699300_jiac437-B32","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1136\/bmj.332.7549.1080","article-title":"The cost of dichotomising continuous variables","volume":"332","author":"Altman","year":"2006","journal-title":"BMJ"},{"key":"2023051202560699300_jiac437-B33","doi-asserted-by":"crossref","first-page":"e11284","DOI":"10.2196\/11284","article-title":"Human papillomavirus infection and transmission among couples through heterosexual activity (HITCH) cohort study: protocol describing design, methods, and research goals","volume":"8","author":"El-Zein","year":"2019","journal-title":"JMIR Res Protoc"},{"key":"2023051202560699300_jiac437-B34","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1373\/clinchem.2005.052381","article-title":"Multiplex human papillomavirus serology based on in situ-purified glutathione S-transferase fusion proteins","volume":"51","author":"Waterboer","year":"2005","journal-title":"Clin Chem"},{"key":"2023051202560699300_jiac437-B35","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1016\/j.vaccine.2021.05.018","article-title":"Post-vaccination HPV seroprevalence among female sexual health clinic attenders in England","volume":"39","author":"Mesher","year":"2021","journal-title":"Vaccine"},{"key":"2023051202560699300_jiac437-B36","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.virol.2009.04.004","article-title":"Enhanced papillomavirus-like particle production in insect cells","volume":"388","author":"Senger","year":"2009","journal-title":"Virology"},{"key":"2023051202560699300_jiac437-B37","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1158\/1055-9965.EPI-07-0349","article-title":"Serologic response to oncogenic human papillomavirus types in male and female university students in Busan, South Korea","volume":"16","author":"Clifford","year":"2007","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2023051202560699300_jiac437-B38","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1750-9378-7-38","article-title":"Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease","volume":"7","author":"Serrano","year":"2012","journal-title":"Infect Agent Cancer"},{"key":"2023051202560699300_jiac437-B39","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/ijc.30716","article-title":"Worldwide burden of cancer attributable to HPV by site, country and HPV type","volume":"141","author":"de Martel","year":"2017","journal-title":"Int J Cancer"},{"key":"2023051202560699300_jiac437-B40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijid.2019.03.022","article-title":"Mucosal and cutaneous human papillomavirus seroprevalence among adults in the prevaccine era in Germany\u2014results from a nationwide population-based survey","volume":"83","author":"Loenenbach","year":"2019","journal-title":"Int J Infect Dis"},{"key":"2023051202560699300_jiac437-B41","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.pvr.2018.03.006","article-title":"Seroprevalence of HPV 6, 11, 16 and 18 and correlates of exposure in unvaccinated women aged 16\u201364 years in Puerto Rico","volume":"5","author":"Ortiz","year":"2018","journal-title":"Papillomavirus Res"},{"key":"2023051202560699300_jiac437-B42","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1016\/j.vaccine.2013.08.038","article-title":"Pre-vaccination seroprevalence of 15 human papillomavirus (HPV) types among women in the population-based Slovenian cervical screening program","volume":"31","author":"U\u010dakar","year":"2013","journal-title":"Vaccine"},{"key":"2023051202560699300_jiac437-B43","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1002\/ijc.28888","article-title":"Antibodies against high-risk human papillomavirus proteins as markers for invasive cervical cancer","volume":"135","author":"Combes","year":"2014","journal-title":"Int J Cancer"},{"key":"2023051202560699300_jiac437-B44","doi-asserted-by":"crossref","first-page":"103123","DOI":"10.1016\/j.ebiom.2020.103123","article-title":"Characterization of human papillomavirus (HPV) 16 E6 seropositive individuals without HPV-associated malignancies after 10 years of follow-up in the UK Biobank","volume":"62","author":"Brenner","year":"2020","journal-title":"EBioMedicine"},{"key":"2023051202560699300_jiac437-B45","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1158\/1055-9965.EPI-14-1217","article-title":"Human papillomavirus 16 E6 antibodies in individuals without diagnosed cancer: a pooled analysis","volume":"24","author":"Lang Kuhs","year":"2015","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2023051202560699300_jiac437-B46","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s13027-022-00418-2","article-title":"HPV types 16\/18 L1 E6 and E7 proteins seropositivity and cervical cancer risk in HIV-positive and HIV-negative black South African women","volume":"17","author":"Singini","year":"2022","journal-title":"Infect Agent Cancer"},{"key":"2023051202560699300_jiac437-B47","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1158\/1055-9965.EPI-10-0336","article-title":"Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the international agency for research on cancer HPV prevalence surveys","volume":"19","author":"Vaccarella","year":"2010","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2023051202560699300_jiac437-B48","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1093\/infdis\/172.6.1584","article-title":"Divergent human papillomavirus type 16 variants are serologically cross-reactive","volume":"172","author":"Cheng","year":"1995","journal-title":"J Infect Dis"},{"volume-title":"The health professional's HPV handbook: human papillomavirus and cervical cancer","year":"2006","author":"Prendiville","key":"2023051202560699300_jiac437-B49"},{"key":"2023051202560699300_jiac437-B50","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1016\/j.vaccine.2017.11.089","article-title":"Immunogenicity of HPV prophylactic vaccines: serology assays and their use in HPV vaccine evaluation and development","volume":"36","author":"Pinto","year":"2018","journal-title":"Vaccine"}],"container-title":["The Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jid\/advance-article-pdf\/doi\/10.1093\/infdis\/jiac437\/47590165\/jiac437.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/227\/10\/1173\/50285544\/jiac437.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jid\/article-pdf\/227\/10\/1173\/50285544\/jiac437.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T02:57:55Z","timestamp":1683860275000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jid\/article\/227\/10\/1173\/6794088"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,2]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,11,2]]},"published-print":{"date-parts":[[2023,5,12]]}},"URL":"https:\/\/doi.org\/10.1093\/infdis\/jiac437","relation":{},"ISSN":["0022-1899","1537-6613"],"issn-type":[{"type":"print","value":"0022-1899"},{"type":"electronic","value":"1537-6613"}],"subject":[],"published-other":{"date-parts":[[2023,5,15]]},"published":{"date-parts":[[2022,11,2]]}}}